Combining the oral drug ixazomib and lower-dose lenalidomide shows important reductions in neutropenia and peripheral ...

"We are well aware that four-drug regimens with anti-CD38 monoclonal antibodies, lenalidomide, proteasome inhibitors, and ...

TORONTO -- A three-drug combination involving the B-cell maturation antigen (BCMA)-CD3 bispecific antibody elranatamab ...

Iberdomide is a member of a new drug class in myeloma known as CELMoD agents, which build on the established platform of ...

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk This multicenter, single ...

An FDA AdCom voted for a new intermediate endpoint of MRD for accelerated approvals in multiple myeloma in 2024.

Bristol Myers Squibb BMY announced positive data from the late-stage study on iberdomide in patients with relapsed or ...

Daratumumab plus VRd and frontline daratumumab plus VTd produced deep, durable responses in patients with transplant-eligible multiple myeloma in updates to the PERSEUS and CASSIOPEIA trials, ...

Second part of the Phase 3 CASSIOPEIA study of daratumumab as maintenance treatment for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant met the primary ...

Please provide your email address to receive an email when new articles are posted on . The addition of subcutaneous daratumumab to triplet therapy improved outcomes in transplant-ineligible or ...

New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPRO® were progression free at 4.5 years Subgroup analysis from Phase 3 ...